Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing

View original at nasdaq.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing Key Points Whitehead sold 3,901 shares for a total transaction value of approximately ~$828K on June 3, 2026…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AMR stock is essentially flat year-to-date as the metallurgical coal market has cooled following several years of tight supply and high demand, and AMR's profit margins have suffered.

    60% confidence
  • Whitehead's average sell-only trade size over the past four events is approximately 18,451 shares; the smaller June 3 sale is explained by reduced remaining share capacity after prior sales.

    60% confidence
  • Alpha Metallurgical Resources was not identified as one of the 10 best stocks for investors to buy now by the Motley Fool Stock Advisor analyst team.

    60% confidence
  • Motley Fool Stock Advisor has a total average return of 941%, outperforming the S&P 500's 206% return.

    60% confidence
  • AMR is likely fairly priced at current levels given the oversupplied metallurgical coal market and current valuation.

    60% confidence
  • Whitehead's prior two open-market sales since January 25, 2025 reflect declining sale sizes as available holdings decrease, with the June 3 sale being the smallest disposition in the last four sell transactions.

    60% confidence
  • AMR's operating margin has slipped to -2.0% after peaking at nearly 50% in 2022.

    60% confidence
  • AMR stock trades at a P/S ratio of 1.2x, above AMR's lifetime average P/S of 0.6x, indicating it is trading at a relative premium.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing — Source | Via News | ViaNews EU